Verano Holdings Corp.

NEOE:VRNO Stock Report

Market Cap: CA$609.9m

Verano Holdings Valuation

Is VRNO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VRNO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CA$13.03
Fair Value
87.3% undervalued intrinsic discount
7
Number of Analysts

Below Fair Value: VRNO (CA$1.66) is trading below our estimate of fair value (CA$13.03)

Significantly Below Fair Value: VRNO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VRNO?

Key metric: As VRNO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VRNO. This is calculated by dividing VRNO's market cap by their current revenue.
What is VRNO's PS Ratio?
PS Ratio0.5x
SalesUS$897.57m
Market CapUS$426.30m

Price to Sales Ratio vs Peers

How does VRNO's PS Ratio compare to its peers?

The above table shows the PS ratio for VRNO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.5x
GUD Knight Therapeutics
1.7x6.5%CA$574.7m
CL Cresco Labs
0.5x1.2%CA$719.9m
CRON Cronos Group
6.9x11.9%CA$1.1b
CPH Cipher Pharmaceuticals
9x14.1%CA$348.3m
VRNO Verano Holdings
0.5x3.2%CA$609.9m

Price-To-Sales vs Peers: VRNO is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (4.5x).

Price to Sales Ratio vs Industry

How does VRNO's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

24 CompaniesPrice / SalesEstimated GrowthMarket Cap
AYR.A Ayr Wellness
0.1x4.0%US$59.46m
TIUM.U FLUENT
0.2xn/aUS$21.05m
FFNT 4Front Ventures
0.2xn/aUS$12.79m
MRV Nuvo Pharmaceuticals
0.2xn/aUS$11.21m
VRNO 0.5xIndustry Avg. 0.8xNo. of Companies24PS012345+
24 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VRNO is good value based on its Price-To-Sales Ratio (0.5x) compared to the Canadian Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is VRNO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VRNO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.5x
Fair PS Ratio0.9x

Price-To-Sales vs Fair Ratio: VRNO is good value based on its Price-To-Sales Ratio (0.5x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VRNO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$1.66
CA$8.30
+400.0%
39.7%CA$13.52CA$4.95n/a7
Jan ’26CA$1.76
CA$8.74
+396.7%
33.4%CA$13.44CA$4.92n/a7
Dec ’25CA$1.93
CA$8.62
+346.8%
32.1%CA$13.06CA$4.79n/a8
Nov ’25CA$4.66
CA$12.88
+176.5%
19.3%CA$16.94CA$9.10n/a8
Oct ’25CA$4.51
CA$12.74
+182.5%
18.4%CA$16.44CA$8.83n/a9
Sep ’25CA$4.44
CA$12.77
+187.7%
19.2%CA$16.94CA$8.80n/a9
Aug ’25CA$5.40
CA$13.13
+143.2%
18.8%CA$17.46CA$9.11n/a9
Jul ’25CA$4.91
CA$13.31
+171.1%
18.7%CA$17.26CA$9.01n/a8
Jun ’25CA$5.61
CA$12.98
+131.4%
18.9%CA$17.17CA$8.96n/a9
May ’25CA$7.04
CA$12.73
+80.8%
15.5%CA$16.63CA$9.13n/a9
Apr ’25CA$8.55
CA$12.64
+47.9%
16.0%CA$16.68CA$9.03n/a9
Mar ’25CA$6.84
CA$12.46
+82.1%
17.8%CA$16.48CA$7.87n/a9
Feb ’25CA$8.80
CA$11.85
+34.7%
15.0%CA$13.92CA$7.78CA$1.808
Jan ’25CA$5.88
CA$11.67
+98.5%
16.7%CA$13.99CA$7.96CA$1.768
Dec ’24CA$5.78
CA$11.67
+102.1%
16.7%CA$13.99CA$7.96CA$1.938
Nov ’24CA$4.54
CA$12.52
+175.9%
17.8%CA$15.45CA$8.25CA$4.668
Oct ’24CA$6.15
CA$12.33
+100.4%
17.9%CA$15.10CA$8.07CA$4.518
Sep ’24CA$5.15
CA$11.99
+132.8%
18.7%CA$14.98CA$8.00CA$4.447
Aug ’24CA$3.88
CA$12.51
+222.3%
21.7%CA$16.90CA$7.87CA$5.407
Jul ’24CA$3.90
CA$12.19
+212.5%
23.3%CA$16.63CA$7.81CA$4.916
Jun ’24CA$3.89
CA$13.85
+256.1%
31.2%CA$22.11CA$8.00CA$5.617
May ’24CA$4.06
CA$13.84
+240.9%
31.4%CA$22.19CA$8.01CA$7.047
Apr ’24CA$3.87
CA$13.66
+253.1%
27.7%CA$22.14CA$7.99CA$8.5510
Mar ’24CA$3.90
CA$15.96
+309.2%
37.7%CA$26.51CA$5.93CA$6.8411
Feb ’24CA$4.15
CA$16.92
+307.6%
33.8%CA$26.20CA$5.86CA$8.8010
Analyst Price Target
Consensus Narrative from 7 Analysts
CA$8.30
Fair Value
80.0% undervalued intrinsic discount
7
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 09:38
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Verano Holdings Corp. is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Capital Markets
Kenric TygheATB Capital Markets